{"organizations": [], "uuid": "3dba02e76cc3bb8e4db93af22b4dec1de64a211a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/2", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/22/pr-newswire-boston-scientific-prices-1-point-0-billion-of-senior-notes.html", "country": "US", "domain_rank": 767, "title": "Boston Scientific Prices $1.0 Billion of Senior Notes", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-23T01:30:00.000+02:00", "replies_count": 0, "uuid": "3dba02e76cc3bb8e4db93af22b4dec1de64a211a"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/22/pr-newswire-boston-scientific-prices-1-point-0-billion-of-senior-notes.html", "ord_in_thread": 0, "title": "Boston Scientific Prices $1.0 Billion of Senior Notes", "locations": [], "entities": {"persons": [], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "marlborough", "sentiment": "none"}], "organizations": [{"name": "boston scientific corporation", "sentiment": "negative"}, {"name": "boston scientific prices", "sentiment": "negative"}, {"name": "nyse", "sentiment": "negative"}, {"name": "boston scientific", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "MARLBOROUGH, Mass., Feb. 22, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $1.0 billion aggregate principal amount of its 4.000% senior notes due March 1, 2028 under the company's shelf registration statement.\nThe company expects to receive the net offering proceeds upon closing on February 26, 2018, subject to customary closing conditions. Boston Scientific intends to use the net proceeds from the offering to redeem its 2.650% notes due October 2018, of which $600 million aggregate principal amount was outstanding as of the date hereof, and to repay short term debt and to pay related fees, expenses and premiums. Any such redemption would be made in accordance with the terms of the applicable indenture, including providing the required notice of redemption.\nNothing herein shall constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such state or jurisdiction. The offering is being made by means of a prospectus and related preliminary prospectus supplement only, copies of which or information concerning this offering may be obtained by contacting the joint book-running managers: Barclays Capital Inc., toll-free at (888) 603-5847; Citigroup Global Markets Inc., toll-free at (800) 831-9146, or Merrill Lynch, Pierce, Fenner & Smith Incorporated, toll free at (800) 294-1322.\nAbout Boston Scientific\nBoston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.\nCautionary Statement Regarding Forward-Looking Statements\nThis press release contains forward-looking statements Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like \"anticipate,\" \"expect,\" \"project,\" \"believe,\" \"plan,\" \"may,\" \"estimate,\" \"intend\" and similar words. These forward- based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our proposed offering and intended use of proceeds. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These , in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual contemplated by the statements expressed in this document. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.\nRisks and uncertainties that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation and governmental investigations; financial market conditions; and future business decisions made by us and our competitors, all of which are difficult or impossible to predict accurately and many of which are beyond our control. For a further list and description of these and other important that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.\nCONTACT:\nMedia:\nKate Haranis\nInvestors:\nSusie Lisa, CFA\n508-683-6585 (office)\n508-683-5565 (office)\nMedia Relations\nInvestor Relations\nBoston Scientific Corporation\nBoston Scientific Corporation\nkate.haranis@bsci.com\nBSXInvestorRelations@bsci.com\nView original content with multimedia: http://www.prnewswire.com/news-releases/boston-scientific-prices-10-billion-of-senior-notes-300603148.html\nSOURCE Boston Scientific Corporation", "external_links": ["http://www.prnewswire.com/news-releases/boston-scientific-prices-10-billion-of-senior-notes-300603148.html"], "published": "2018-02-23T01:30:00.000+02:00", "crawled": "2018-02-23T03:18:52.011+02:00", "highlightTitle": ""}